Business
Lattice Biologics Upgraded to OTCQB Venture Market
Lattice Biologics Upgraded to OTCQB Venture Market.
About this update from Lattice Biologics Ltd
[{"type":"text","content":"\nLattice Biologics Upgraded to OTCQB Venture Market\n\nLattice Biologics Upgraded to OTCQB Venture Market\n\nSCOTTSDALE, AZ--(Marketwired - February 01, 2017) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (\"Lattice Biologics\" or the \"Company\") is pleased to announce that the Company has been approved to upgrade its common shares from the Pink Open Market to the OTCQB® Venture Market under the trading symbol \"LBLTF\", effective January 31, 2017.CEO Guy Cook commented, \"Upgrading to the OTCQB is a very positive step forward for the Company. The upgrade confirms our commitment to our growing United States shareholder base and will improve the trading experience for investors.\"About OTCQB®:The OTCQB® Venture Market, operated by OTC Markets Group Inc., requires companies to remain current and compliant in their reporting, and undergo an annual verification and management certification process. These standards provide improved investor confidence through verified information, as well as greater information availability, and transparent prices for investors with Real Time Level 2 quotes.U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for Lattice Biologics at http://www.otcmarkets.com/stock/LBLTF/quote.Lattice Biologics Ltd.Guy Cook, Chief Executive OfficerTelephone No: (480) 563-0800About Lattice Biologics Ltd.:Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes. Versatile allografts for a variety of surgical applications:Enhancing fusion in spine surgeryEnhancing breast reconstruction post mastectomy for breast cancer patientsSports medicine indications, including ACL repairPromotion of bone regeneration in foot and ankle surgeryPromotion of cranial healing following neurosurgeryEnhancing wound repair in burn victimsSubchondral bone defect repair in knee and other joint surgeriesThe Company is currently exploring new technologies in regenerative and personalized medicine: All natural amniotic fluid supplement for arthritic joints Demonstrates lasting pain relief and improved outcomes in the largest clinical stu...